NCT04427787

A Trial Aiming to Assess the Safety and Activity of the Combination of Cabozantinib Plus Lanreotide in GEP and NET

A Phase II Trial Aiming to Assess the Safety and Activity of the Combination of Cabozantinib Plus Lanreotide in Gastroenteropancreatic (GEP) and Thoracic Neuroendocrine Tumor (NET): The LOLA Trial

• Status: Unknown
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 69 (estimated)
• Sponsor: Fondazione IRCCS Istituto Nazionale dei Tumori, Milano · Academic / Other
• Sex: All
• Age: 18 Years – 90 Years
• Healthy volunteers: Not accepted

Summary

A Phase II trial aiming to assess the safety and activity of the combination of cabozantinib plus lanreotide in gastroenteropancreatic (GEP) and thoracic neuroendocrine tumor (NET): The LOLA trial

Detailed description

Phase II, multicenter, open-label, non-comparative, non-randomized study with three-stage design

Conditions

• Metastatic Well Differentiated Neuroendocrine Neoplasm
• Neuroendocrine Tumors

Interventions

Type	Name	Description
DRUG	Cabozantinib	Cabozantinib will be administered orally at a dose of 60 mg/day
DRUG	Lanreotide	Lanreotide will be administrated 120 mg injection every 28 days

Timeline

• Start date: 2020-06-20
• Primary completion: 2023-11-01
• Completion: 2023-11-01
• First posted: 2020-06-11
• Last updated: 2021-09-05

Locations

1 site across 1 country: Italy